Press Release: Tarveda : Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221 to Be Presented at NANETS 2021 Multidisciplinary NET Virtual Symposium
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda announces that data from the Phase 2 trial of PEN-221 will be presented at the NANETS 2021 Multidisciplinary NET Medical Virtual Symposium.
Read full article »
Tarveda is a biopharmaceutical company that discovers and develops miniaturized drug conjugates for the treatment of solid tumor malignancies.
Read more